Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Heron Therapeutics Inc Common Stock (HRTX).
- Disclosed ownership: 4.6%.
- Date of event: 30 Sep 2025.
VANGUARD GROUP INC - 30 Sep 2025 SCHEDULE 13G/A Report for Heron Therapeutics Inc Common Stock (HRTX)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- Heron Therapeutics Inc Common Stock
- Symbol
- HRTX
- Shares outstanding
- 183,509,414 shares
- Disclosed Ownership
- 8,459,784 shares
- Ownership
- 4.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 30 Oct 2025, 15:16:56 UTC
- Date of event
- 30 Sep 2025
- Next filing
- 30 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 4.6% ownership in Heron Therapeutics Inc Common Stock (HRTX) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 Oct 2025, 15:16.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 4.6% | 8,459,784 | 0 | 917,424 | Ashley Grim | Head of Global Fund Administration |